Published in PLoS One on August 06, 2008
HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol (2010) 2.24
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal (2009) 2.23
Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network. PLoS One (2013) 2.01
Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res (2010) 1.32
Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res (2009) 1.26
Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress. Mol Pharmacol (2012) 1.08
Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling. PLoS One (2010) 1.03
ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget (2014) 1.02
EGFR juxtamembrane domain, membranes, and calmodulin: kinetics of their interaction. Biophys J (2009) 0.99
Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers. Oncotarget (2011) 0.98
Cancer stem cell, niche and EGFR decide tumor development and treatment response: A bio-computational simulation study. J Theor Biol (2010) 0.98
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget (2013) 0.97
Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One (2013) 0.94
Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Mol Pharmacol (2012) 0.89
Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget (2014) 0.89
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer (2014) 0.87
HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways. Protein Cell (2012) 0.86
Versican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapy. PLoS One (2011) 0.84
Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells. Br J Cancer (2009) 0.83
The Potential of panHER Inhibition in Cancer. Front Oncol (2015) 0.80
Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer. Oncotarget (2015) 0.80
Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models. Invest New Drugs (2011) 0.78
Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts. Radiat Oncol (2014) 0.78
Synergistic enhancement of the potency and selectivity of small molecule transcriptional inhibitors. ACS Med Chem Lett (2012) 0.75
Role of traditional and new biomarkers in breast carcinogenesis. Ecancermedicalscience (2009) 0.75
FEN1 knockdown improves trastuzumab sensitivity in human epidermal growth factor 2-positive breast cancer cells. Exp Ther Med (2017) 0.75
Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis. Breast Cancer Res Treat (2017) 0.75
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol (2006) 10.39
The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J (2000) 9.51
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J (1997) 5.70
gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (2001) 4.90
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell (2006) 3.20
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res (2001) 3.18
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology (2003) 3.17
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res (2001) 3.02
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2003) 2.85
Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist (2002) 2.62
The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol (2004) 2.41
Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol (2007) 2.28
Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol (2006) 2.17
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol (2002) 2.14
ErbB-4: mechanism of action and biology. Exp Cell Res (2003) 1.91
Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol (2001) 1.80
Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene (2007) 1.69
The epidermal growth factor receptor family. Endocr Relat Cancer (2005) 1.55
Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J Biol Chem (1991) 1.48
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer (2001) 1.46
Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene (1999) 1.39
Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem (1997) 1.38
Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet (1989) 1.37
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res (2003) 1.35
Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer (2005) 1.35
Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther (2004) 1.25
Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res (2007) 1.20
Constitutive proteolysis of the ErbB-4 receptor tyrosine kinase by a unique, sequential mechanism. J Cell Biol (1997) 1.20
Heregulin-dependent trafficking and cleavage of ErbB-4. J Biol Chem (2000) 1.18
Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment. J Biol Chem (2003) 1.17
Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res (2006) 1.12
EGF regulation of PITP dynamics is blocked by inhibitors of phospholipase C and of the Ras-MAP kinase pathway. Curr Biol (2003) 1.08
Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res (1997) 1.00
Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Cancer Res (1999) 0.94
Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing. Ann Oncol (2002) 0.87
HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4. Cancer Res (2007) 0.85
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat Struct Mol Biol (2009) 3.37
Svp1p defines a family of phosphatidylinositol 3,5-bisphosphate effectors. EMBO J (2004) 2.73
A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biol (2010) 2.72
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res (2008) 2.56
Recognition of an intra-chain tandem 14-3-3 binding site within PKCepsilon. EMBO Rep (2009) 2.55
PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol (2010) 2.41
Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol (2007) 2.28
HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol (2010) 2.24
A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res (2008) 2.16
Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol (2009) 2.15
A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol (2011) 2.11
A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. EMBO Rep (2008) 2.09
Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res (2008) 2.06
Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem (2006) 1.91
Integrin-specific signaling pathways controlling focal adhesion formation and cell migration. J Cell Biol (2003) 1.90
14-3-3 proteins interact with a hybrid prenyl-phosphorylation motif to inhibit G proteins. Cell (2013) 1.90
Monitoring conformational changes of proteins in cells by fluorescence lifetime imaging microscopy. Biochem J (2003) 1.89
The late endosome is essential for mTORC1 signaling. Mol Biol Cell (2010) 1.79
PKCepsilon-mediated phosphorylation of vimentin controls integrin recycling and motility. EMBO J (2005) 1.75
The identification and characterization of novel PKCepsilon phosphorylation sites provide evidence for functional cross-talk within the PKC superfamily. Biochem J (2008) 1.74
Emerging and diverse roles of protein kinase C in immune cell signalling. Biochem J (2003) 1.69
Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics (2005) 1.69
PKC epsilon controls the traffic of beta1 integrins in motile cells. EMBO J (2002) 1.67
FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J (2006) 1.61
The regulated assembly of a PKCepsilon complex controls the completion of cytokinesis. Nat Cell Biol (2008) 1.61
PtdIns-specific MPR pathway association of a novel WD40 repeat protein, WIPI49. Mol Biol Cell (2004) 1.57
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res (2003) 1.55
PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO J (2004) 1.51
Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol (2008) 1.48
An aPKC-exocyst complex controls paxillin phosphorylation and migration through localised JNK1 activation. PLoS Biol (2009) 1.48
Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res (2012) 1.42
The structural dilemma of bulk polyethylene: an intermediary structure. PLoS One (2009) 1.40
Nucleotide binding by the Mdm2 RING domain facilitates Arf-independent Mdm2 nucleolar localization. Mol Cell (2003) 1.39
Site-directed perturbation of protein kinase C- integrin interaction blocks carcinoma cell chemotaxis. Mol Cell Biol (2002) 1.35
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res (2002) 1.23
Nintendo Wii video-gaming ability predicts laparoscopic skill. Surg Endosc (2010) 1.23
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res (2009) 1.20
mTORC2 targets AGC kinases through Sin1-dependent recruitment. Biochem J (2011) 1.18
Phosphatidylinositol 3-kinase C2alpha is essential for ATP-dependent priming of neurosecretory granule exocytosis. Mol Biol Cell (2005) 1.16
Protein kinase C controls microtubule-based traffic but not proteasomal degradation of c-Met. J Biol Chem (2003) 1.13
Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res (2006) 1.12
Appendiceal faecaliths are associated with right iliac fossa pain. Ann R Coll Surg Engl (2010) 1.12
Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res Treat (2003) 1.12
PKC alpha protein but not kinase activity is critical for glioma cell proliferation and survival. Int J Cancer (2008) 1.11
Protein kinase C intervention: the state of play. Curr Opin Cell Biol (2009) 1.11
Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer. Oncogene (2005) 1.11
PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J Clin Invest (2010) 1.09
Protein kinase C phosphorylates ribosomal protein S6 kinase betaII and regulates its subcellular localization. Mol Cell Biol (2003) 1.08
PKCepsilon regulation of an alpha5 integrin-ZO-1 complex controls lamellae formation in migrating cancer cells. Sci Signal (2009) 1.08
Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. J Pathol (2004) 1.06
Phosphatidylinositol metabolism and membrane fusion. Biochem J (2009) 1.06
A targeted siRNA screen identifies regulators of Cdc42 activity at the natural killer cell immunological synapse. Sci Signal (2011) 1.05
3-D structure and dynamics of protein kinase B-new mechanism for the allosteric regulation of an AGC kinase. J Chem Biol (2009) 1.05
Dephosphorylation of PKCdelta by protein phosphatase 2Ac and its inhibition by nucleotides. FEBS Lett (2002) 1.04
Endothelial alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF. Am J Pathol (2010) 1.02
Calmodulin controls organization of the actin cytoskeleton via regulation of phosphatidylinositol (4,5)-bisphosphate synthesis in Saccharomyces cerevisiae. Biochem J (2002) 1.02
PKCα and PKCδ regulate ADAM17-mediated ectodomain shedding of heparin binding-EGF through separate pathways. PLoS One (2011) 1.00
The scaffold MyD88 acts to couple protein kinase Cepsilon to Toll-like receptors. J Biol Chem (2008) 0.99
Regulatory domain selectivity in the cell-type specific PKN-dependence of cell migration. PLoS One (2011) 0.99
Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother (2009) 0.99
PIKfyve negatively regulates exocytosis in neurosecretory cells. J Biol Chem (2007) 0.99
Regulation of 3-phosphoinositide-dependent protein kinase 1 activity by homodimerization in live cells. Sci Signal (2010) 0.99
Nuclear envelope remnants: fluid membranes enriched in sterols and polyphosphoinositides. PLoS One (2009) 0.99
Phosphorylation is required for PMA- and cell-cycle-induced degradation of protein kinase Cdelta. Biochem J (2002) 0.98
Acute manipulation of diacylglycerol reveals roles in nuclear envelope assembly & endoplasmic reticulum morphology. PLoS One (2012) 0.98
Detecting protein-phospholipid interactions. Epidermal growth factor-induced activation of phospholipase D1b in situ. J Biol Chem (2002) 0.97
Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients. Int J Cancer (2006) 0.97
PKCepsilon is a permissive link in integrin-dependent IFN-gamma signalling that facilitates JAK phosphorylation of STAT1. Nat Cell Biol (2003) 0.97
PLCgamma is enriched on poly-phosphoinositide-rich vesicles to control nuclear envelope assembly. Cell Signal (2006) 0.96
Hyperosmotic-induced protein kinase N 1 activation in a vesicular compartment is dependent upon Rac1 and 3-phosphoinositide-dependent kinase 1. J Biol Chem (2003) 0.95
Human epidermal growth factor receptor (EGFR) aligned on the plasma membrane adopts key features of Drosophila EGFR asymmetry. Mol Cell Biol (2011) 0.94
Notch regulation of tumor angiogenesis. Future Oncol (2011) 0.93
Novel phosphorylation site markers of protein kinase C delta activation. FEBS Lett (2007) 0.92
Spatial regulation of membrane fusion controlled by modification of phosphoinositides. PLoS One (2010) 0.92
ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines. J Cell Sci (2013) 0.92
Control of MT1-MMP transport by atypical PKC during breast-cancer progression. Proc Natl Acad Sci U S A (2014) 0.91
Molecular dissection of the interaction between the small G proteins Rac1 and RhoA and protein kinase C-related kinase 1 (PRK1). J Biol Chem (2003) 0.91
Identification of PKCzetaII: an endogenous inhibitor of cell polarity. EMBO J (2003) 0.90
Revealing signaling in single cells by single- and two-photon fluorescence lifetime imaging microscopy. Methods Mol Biol (2009) 0.89
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res (2012) 0.89
Protein kinase C epsilon in cell division: control of abscission. Cell Cycle (2009) 0.89
Adenosine-binding motif mimicry and cellular effects of a thieno[2,3-d]pyrimidine-based chemical inhibitor of atypical protein kinase C isoenzymes. Biochem J (2013) 0.88
Nuclear envelope assembly is promoted by phosphoinositide-specific phospholipase C with selective recruitment of phosphatidylinositol-enriched membranes. Biochem J (2005) 0.87
Potentiation of protein kinase C zeta activity by 15-deoxy-delta(12,14)-prostaglandin J(2) induces an imbalance between mitogen-activated protein kinases and NF-kappa B that promotes apoptosis in macrophages. Mol Cell Biol (2003) 0.87
Acute cholecystits leading to ischemic ECG changes in a patient with no underlying cardiac disease. JSLS (2011) 0.86